| Literature DB >> 32518659 |
Iwan Harries1, Jonathan R Weir-McCall2, Michelle C Williams3, James Shambrook4, Giles Roditi5, Russel Bull6, Gareth J Morgan-Hughes7, Edward D Nicol8, Alastair J Moss9.
Abstract
Objective: This cross-sectional observational study sought to describe variations in CT in the context of transcatheter aortic valve implantation (CT-TAVI) as currently performed in the UK.Entities:
Keywords: CT scanning; aortic valve disease; percutaneous valve therapy
Mesh:
Year: 2020 PMID: 32518659 PMCID: PMC7254150 DOI: 10.1136/openhrt-2019-001233
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Figure 1Geographical distribution of survey respondents. Cardiac CT centres from England, Scotland, Wales and Northern Ireland provided survey data (A). Sixty-five per cent of respondents worked in centres that provided a transcatheter aortic valve implantation (TAVI) programme (B). Annualised activity varied across centres with non-TAVI centres performing <100 scans per annum (C).
Figure 2CT-TAVI scan acquisition protocols. Image acquisition protocols according to centre type (A). Phase of measurement reporting according to centre type (B). TAVI, transcatheter aortic valve implantation.
Estimated contrast volumes and dose length product (DLP) for the last five CT-TAVI scans performed at each centre and radiation doses according to scan protocol
| Overall | TAVI centres (n=22) | Non-TAVI centres (n=9) | P value | |
| Contrast volume (mL) | 100 (80–130) | 95 (74–120) | 110 (88–160) | 0.06 |
| DLP (mGy.cm) | 675 (477–954) | 550 (423–939) | 700 (538–1075) | 0.66 |
Values are median and IQR.
*P=0.003, **p=0.002, both versus prospective ECG-gated narrow padding.
TAVI, transcatheter aortic valve implantation.
Measurements and structures typically included in the CT-TAVI report at each centre
| Overall (n=38) | TAVI centres (n=26) | Non-TAVI centres (n=12) | P value | |
| Aortic annulus circumference | 21 (55%) | 16 (62%) | 5 (42%) | 0.25 |
| Aortic annulus area | 24 (63%) | 17 (65%) | 7 (58%) | 0.675 |
| Aortic annulus diameter (perimeter derived) | 23 (61%) | 17 (65%) | 6 (50%) | 0.367 |
| Aortic annulus diameter (area derived) | 19 (50%) | 13 (50%) | 6 (50%) | 1.0 |
| Minimum short-axis measurement | 20 (53%) | 14 (54%) | 6 (50%) | 0.82 |
| Minimum short-axis measurement | 20 (53%) | 13 (50%) | 7 (58%) | 0.63 |
| Extent and distribution of aortic root calcification | 31 (82%) | 22 (85%) | 9 (75%) | 0.48 |
| Number of valve cusps (eg, bicuspid, tricuspid) | 32 (84%) | 22 (85%) | 10 (83%) | 0.92 |
| Distance (height) from aortic annulus to LMS ostium | 30 (79%) | 21 (81%) | 9 (75%) | 0.69 |
| Distance (height) from aortic annulus to RCA ostium | 30 (79%) | 21 (81%) | 9 (75%) | 0.69 |
| Distance (height) from aortic annulus to sinotubular junction (left cusp) | 11 (29%) | 6 (23%) | 5 (42%) | 0.24 |
| Distance (height) from aortic annulus to sinotubular junction (right cusp) | 9 (24%) | 5 (19%) | 4 (33%) | 0.34 |
| Distance (height) from aortic annulus to sinotubular junction (non-coronary cusp) | 7 (18%) | 4 (15%) | 3 (25%) | 0.48 |
| Presence of LVH | 23 (61%) | 18 (69%) | 5 (42%) | 0.17 |
| Ascending aorta diameter | 31 (82%) | 21 (81%) | 10 (83%) | 0.85 |
| Descending and abdominal aorta (tortuosity, intraluminal obstruction, calcification) | 31 (82%) | 23 (88%) | 8 (67%) | 0.11 |
| Subclavian and brachiocephalic artery diameter | 18 (47%) | 16 (62%) | 2 (17%) | |
| Minimum iliofemoral artery luminal diameter | 32 (84%) | 25 (96%) | 7 (58%) | |
| Iliofemoral artery patency | 32 (84%) | 24 (92%) | 8 (67%) | |
| Iliofemoral artery tortuosity | 31 (82%) | 24 (92%) | 7 (58%) | |
| Optimal tube angulation data to inform fluoroscopic projection for device deployment | 13 (34%) | 12 (46%) | 1 (8%) |
Values are count (n) and percentage (%).
Bold values indicate statistical significance at a p value <0.05
LMS, left main stem; LVH, left ventricular hypertrophy; RCA, right coronary artery; TAVI, transcatheter aortic valve implantation.
Figure 3Dissemination of findings to Heart Team. Heart Team multidisciplinary discussions were present at 76% of centres overall (A). When Heart Team discussions were in place, a cardiac imaging specialist was ‘always present’ at 57% of meetings (B). There was a significant difference in the provision of Heart Team meetings at TAVI and non-TAVI centres (96%, n=24/25 vs 33%, n=4/12, p<0.001) (C). TAVI, transcatheter aortic valve implantation.